- Home
- LYEL vs AVR Comparison
LYEL vs AVR Comparison
Compare LYEL & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- AVR
- Stock Information
- Founded
- LYEL 2018
- AVR 1999
- Country
- LYEL United States
- AVR Australia
- Employees
- LYEL N/A
- AVR N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- AVR
- Sector
- LYEL Health Care
- AVR
- Exchange
- LYEL Nasdaq
- AVR NYSE
- Market Cap
- LYEL 207.7M
- AVR 241.5M
- IPO Year
- LYEL 2021
- AVR 2024
- Fundamental
- Price
- LYEL $0.44
- AVR $4.24
- Analyst Decision
- LYEL Sell
- AVR Strong Buy
- Analyst Count
- LYEL 2
- AVR 4
- Target Price
- LYEL $1.00
- AVR $16.50
- AVG Volume (30 Days)
- LYEL 627.4K
- AVR 148.4K
- Earning Date
- LYEL 05-13-2025
- AVR 05-13-2025
- Dividend Yield
- LYEL N/A
- AVR N/A
- EPS Growth
- LYEL N/A
- AVR N/A
- EPS
- LYEL N/A
- AVR N/A
- Revenue
- LYEL $65,000.00
- AVR $2,493,000.00
- Revenue This Year
- LYEL N/A
- AVR $29.52
- Revenue Next Year
- LYEL N/A
- AVR $204.83
- P/E Ratio
- LYEL N/A
- AVR N/A
- Revenue Growth
- LYEL N/A
- AVR N/A
- 52 Week Low
- LYEL $0.39
- AVR $2.34
- 52 Week High
- LYEL $2.80
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- LYEL 51.63
- AVR N/A
- Support Level
- LYEL $0.39
- AVR N/A
- Resistance Level
- LYEL $0.43
- AVR N/A
- Average True Range (ATR)
- LYEL 0.03
- AVR 0.00
- MACD
- LYEL 0.00
- AVR 0.00
- Stochastic Oscillator
- LYEL 83.39
- AVR 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.